Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of brexpiprazole orally disintegrating vs conventional tablets in healthy males
jRCT2080223296Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole in Schizophrenia Spectrum Disorders (SSD) and major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Brexpiprazole Cmax bioequivalence, Brexpiprazole AUCt bioequivalence and 1 more. Started Aug 2016; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Schizophrenia Spectrum Disorders (SSD)major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080223296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223296.